Bayer Receives FDA Approval After
Selected Abstract
Bayer Receives FDA Approval After Expedited Review for Hepatitis C Viral Load Assay, VERSANT(R) HCV RNA 3.0 Assay (bDNA).
TARRYTOWN, NEW YORK, Apr 3, 2003 (CCNMatthews via COMTEX) First and Only FDA-Approved Quantitative HCV Viral Load Assay The Diagnostics Division of Bayer HealthCare LLC, a member of the Bayer Group (NYSE: BAY), announced today that it has received premarket approval after expedited review from the ... April 3, 2003; Canadian Corporate News
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Bayer Receives FDA Approval After Expedited Review for Hepatitis C Viral Load Assay, VERSANT(R) HCV RNA 3.0 Assay (bDNA).
2.
Bayer Receives FDA Approval After Expedited Review For Hepatitis C Viral Load Assay, VERSANT(R) HCV RNA 3.0 Assay (bDNA); First and Only FDA-Approved Quantitative HCV Viral Load Assay.
|
